Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Giulia Ceccardi
Institution:
Azienda Socio Sanitaria Territoriale di Cremona
Observed institutions:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,
IRCCS Ospedale San Raffaele,
Azienda Socio Sanitaria Territoriale di Cremona,
University of Brescia
ORCID:
0000-0003-1595-3894
Observed ORCID:
0000-0003-1595-3894
OpenAlex ID:
A5042509263
Clinical features and outcomes of the flail arm and flail leg and pure lower motor neuron MND variants: a multicentre Italian study
2020
·
Paride Schito
, Giulia Ceccardi
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
31
An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor
2023
·
Francesca Schiano di Cola
, Marco Bolchini
, et al.
·
European Journal of Neurology
·
30
Post COVID-19 vaccination headache: A clinical and epidemiological evaluation
2022
·
Giulia Ceccardi
, Francesca Schiano di Cola
, et al.
·
Frontiers in Pain Research
·
19
PDF
Photophobia and migraine outcome during treatment with galcanezumab
2023
·
Francesca Schiano di Cola
, Giulia Ceccardi
, et al.
·
Frontiers in Neurology
·
12
PDF
Plasma levels of glial fibrillary acidic protein and neurofilament light chain in patients with chronic migraine: a multicenter case-control study
2025
·
Eleonora Colombo
, Alberto Doretti
, et al.
·
Neurological Sciences
·
10
Increased risk of functional neurological disorders following SARS‐CoV‐2 vaccination
2024
·
Andrea Pilotto
, Marcello Catania
, et al.
·
European Journal of Neurology
·
9
PDF
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
2023
·
Francesca Schiano di Cola
, Marco Bolchini
, et al.
·
Neurology International
·
9
PDF
Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational study.
2025
·
Marco Bolchini
, Giulia Ceccardi
, et al.
·
Neurological Sciences
·
6
Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine
2023
·
Giulia Ceccardi
, Francesca Schiano di Cola
, et al.
·
Toxins
·
5
PDF
Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab
2022
·
Marco Bolchini
, Francesca Schiano di Cola
, et al.
·
European Neurology
·
4
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
2022
·
Francesca Schiano di Cola
, Salvatore Caratozzolo
, et al.
·
Neurological Sciences
·
4
PDF
Tracking migraine outcomes over time by age and monoclonal antibody type: a retrospective, single-center, real-world study
2026
·
Irene Mattioli
, Alessandro Rondina
, et al.
·
Frontiers in Neurology
PDF
Could galcanezumab modulate inflammatory cytokines? A single-centre exploratory study
2026
·
Giulia Ceccardi
, Renata Rao
, et al.
·
Journal of Neurology
PDF
Show more works
View as search
Works count:
13
Citation count:
139
H-index:
7
I10-index:
5
Year
Topic
Type